Sodium polystyrene sulfonate: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Fix SMW query: use mainlabel=- to hide subobject column with broken fragment links; Indication column links directly to disease page) |
||
| Line 57: | Line 57: | ||
|format=broadtable | |format=broadtable | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Revision as of 17:20, 20 March 2026
General
- Type:
- Dosage Forms:
- Common Trade Names: Kayexalate
Adult Dosing
Hyperkalemia
- 30 gm oral or per rectum
Pediatric Dosing
- >1mo: 1 g/kg PO or PR q6hr PRN
Special Populations
- Pregnancy Rating: B
- Lactation: Not absorbed systemically so infant risk minimal
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
- Hypokalemia
- Obstructive bowel disease, reduced gut motility
- Rectal administration in neonates, particularly if premature
Adverse Reactions
Serious
- Intestinal necrosis, ulceration, perforation, fecal impaction
- Bezoars
Common
- Abdominal pain, nausea/vomiting, constipation, GI disturbance
- Hypokalemia
- Hypocalcemia
- Hypomagnesemia
- Sodium retention
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: Cation exchange resin, sodium ions partially released from polystyrene and replaced by potassium
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
See Also
- Alternative Sodium zirconium cyclosilicate (Lokelma)